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Background: An adverse intrauterine environment leads to permanent physiological changes including vascular
tone regulation, potentially influencing the risk for adult vascular diseases. We therefore aimed to monitor
responsive NOS3 expression in human umbilical artery endothelial cells (HUAEC) and to study the underlying
epigenetic signatures involved in its regulation.
Results: NOS3 and STAT3 mRNA levels were elevated in HUAEC of patients who suffered from placental insufficiency.
5-hydroxymethylcytosine, H3K9ac and Histone 2A (H2A).Zac at the NOS3 transcription start site directly correlated
with NOS3 mRNA levels. Concomitantly, we observed entangled histone acetylation patterns and NOS3 response
upon hypoxic conditions in vitro. Knock-down of either NOS3 or STAT3 by RNAi provided evidence for a functional
NOS3/STAT3 relationship. Moreover, we recognized massive turnover of Stat3 at a discrete binding site in the NOS3
promoter. Interestingly, induced hyperacetylation resulted in short-termed increase of NOS3 mRNA followed by
deferred decrease indicating that NOS3 expression could become self-attenuated by co-expressed intronic 27
nt-ncRNA. Reporter assay results and phylogenetic analyses enabled us to propose a novel model for STAT3-3′-UTR
targeting by this 27-nt-ncRNA.
Conclusions: An adverse intrauterine environment leads to adaptive changes of NOS3 expression. Apparently, a rapid
NOS3 self-limiting response upon ectopic triggers co-exists with longer termed expression changes in response
to placental insufficiency involving differential epigenetic signatures. Their persistence might contribute to impaired
vascular endothelial response and consequently increase the risk of cardiovascular disease later in life.
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Epidemiological evidence suggests that early environmental
factors such as placental insufficiency correlate with
increased disease risks later in life, e.g. cardiovascular
disease [1]. The phenotypic changes conveying these
risks are necessarily due to deregulated expression of
specific genes during the acute phase of the insult. Gene
expression changes are known to be strongly associated
with the plasticity of chromatin, whose structure can be
influenced by CG dinucleotide (CpG) signalling and
post-translational modifications (PTMs) of histones. Their* Correspondence: andreas.jenke@helios-kliniken.de
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unless otherwise stated.combinatorial signatures control the spatiotemporal expres-
sion of genes in a potentially heritable way. In more
detail, desoxyribonucleic acid (DNA) methylation targets
cytosines (5-methylcytosine (5meC)) predominantly at
isolated asymmetric CpG motifs (‘open sea’) or in the
genomic context of so-called ‘CpG islands’ and adjacent
regions (‘shores/shelves’) [2-4]. 5meC enrichment in
promoters is frequently associated with transcriptional
repression [5]. Recently, hydroxymethylated cytosines
(5-hydroxymethylcytosine (5hmeC)) were recognized as
another functional DNA modification. Currently, the most
widely accepted hypothesis is that 5hmeC is an intermedi-
ate state of active DNA demethylation conferred by mem-
bers of the Tet protein family [6] and thus influencing geneal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lation is conveyed by PTMs of histones, which occur in a
dynamic fashion through variable combinations at a given
site. PTMs can influence chromatin compaction either
directly or in conjunction with ‘reader’ proteins, thus
regulating either activation or repression of genes [9].
The placenta represents the interface between the foetal
and maternal organism. Its perfusion is therefore closely
linked to foetal well-being and critically influences foetal
development [10]. One important factor influencing short-
and long-term placental perfusion is hypoxia [11-13], repre-
senting the most adverse intrauterine milieu for the foetus.
In response—particularly in chronic hypoxia [14]—foetal
circulation compensatory mechanisms involve nitric oxide
(NO) synthesis by endothelial nitric oxide synthase (eNOS),
which eventually contributes to blood vessel tone regula-
tion. NOS3 mRNA synthesis, which gives rise to the eNOS
protein, was recently found to be diminished in response
to hypoxia in human umbilical vein endothelial cells
(HUVEC) [15]. In contrast, NOS3 mRNA was increased in
human umbilical artery endothelial cells (HUAEC) [16]. On
the molecular level, NOS3 expression and eNOS activation
are complex, mainly mediated by PI3K/Akt- or AC/PKA-
signalling involving transcriptional, post-transcriptional and
post-translational factors [17,18]. Attributes of current
short-term regulation concepts involve rapid modulation of
NOS3 mRNA stability or activation of the eNOS protein
via serine phosphorylation [19]. Adaptations to long-term
stimuli (e.g. chronic hypoxia) apparently involve regulation
on the transcriptional level and hence epigenetic plasticity
[20]. Recently, it has been shown in cell culture experi-
ments that hypoxic repression of eNOS transcription in
HUVEC is coupled with eviction of promoter histones [21].
Further detailed insights into this aspect of NOS3/eNOS
regulation are lacking to date, particularly in relation to its
corresponding clinical significance.
We therefore undertook comprehensive analyses on the
regulation of NOS3 expression in foetal HUAEC cells.
This included NOS3 mRNA quantification, genotypingTable 1 Epidemiological characteristics
Total (n = 39) Flow group 0 (n = 10) Flow
Gestational age (SD) 31.9 ± 4.9 31.8 ± 4.8 31.6
Birth weight in g (SD) 1,655 ± 917 1,746 ± 1,008 1,65
Birth length in cm (SD) 41.4 ± 6.1 41.0 ± 7.1 40.7
Maternal age (SD) 31.9 ± 4.9 31.8 ± 4.8 31.6
Ponderal index 21.9 ± 3.5 23.3 ± 2.8 22.9
Apgar at 5 min 8.5 ± 1.2 8.5 ± 1.4 8.7 ±
pH at birth 7.34 ± 1.1 7.34 ± 1.2 7.33
Female (%) 54 42 58
HELLP syndrome (%) 7.7 - -
Preeclampsia (%) 15.4 - 8.3of an intronic putative non-coding RNA (ncRNA) locus
suspicious for pathomechanistic relevance in cardiovas-
cular diseases [22], monitoring of CpG signalling at the
NOS3 promoter and quantification of PTMs relevant
for chromatin structure regulation. We further tested a yet
sparsely evidenced connection between Stat3 signalling
and NOS3/eNOS regulation [23].
Results
Impaired placental perfusion is associated with enriched
NOS3 mRNA independent of tandem repeat
polymorphisms of the NOS3 intronic 27 nt-ncRNA
Thirty-nine infants were included in this study. Placental
and foetal perfusion indices were assessed from all pa-
tients within 24 h prior to delivery and classified to have
either normal flow patterns (group 0; n = 10), mild (group
1; n = 12), moderate (group 2; n = 10) or severe impairment
(group 3; n = 7) (Table 1). Epidemiological parameters such
as maternal age, parity, birth weight, gestational age (GA),
pH and Apgar at 5 min did not differ between the groups
(except from the ponderal index) (Table 1). From all
patients, HUAEC could be isolated to obtain sufficient
amounts of ribonucleic acid (RNA) for cDNA synthesis
and gDNA for genotyping. Amounts of gDNA were suit-
able from 13 patients to enable (h)methylated DNA immu-
noprecipitation (MeDIP). Quantitative real-time PCR
(qPCR) revealed that NOS3 mRNA levels differed signifi-
cantly between the flow groups, whereas NOS2 mRNA
levels, encoding inducible nitric oxide synthase (iNOS), did
not vary (data not shown). Lowest NOS3 mRNA levels
were observed in patients with normal placental perfusion
(group 0, median 13.5 copies per PECAM1, 2.8–37.6) and
highest in patients with severely impaired placental perfu-
sion (group 3, median 218.7 copies per PECAM, 107–386)
(Figure 1A). In all cases, levels also correlated with total
cellular eNOS and eNOS(Ser1177ph) protein levels
(Figure 1B). Since copy number polymorphisms of a 27-bp
tandem repeat (variable number tandem repeat (VNTR))
in intron 5 had previously been associated with adultgroup 1 (n = 12) Flow group 2 (n = 10) Flow group 3 (n = 7)
± 5.7 32.1 ± 4.9 31.2 ± 4.6
2 ± 810 1,636 ± 909 1,336 ± 657
± 6.1 41.9 ± 5.5 40.7 ± 5.2
± 5.7 31.2 ± 4.9 31.2 ± 4.6
± 3.5 19.7 ± 3.0 18.8 ± 1.98
1.3 8.4 ± 1.3 8.3 ± 1.1




Figure 1 NOS3 mRNA correlates with placental perfusion indices and does not depend on NOS3 intronic 27 nt-ncRNA polymorphism.
(A) NOS3 mRNA levels increased >15-fold in patients suffering from severe impairment of placental perfusion (group 3). (B) Protein levels of eNOS and
eNOS(Ser1177ph) correlated with NOS3 mRNA levels. NOS3 mRNA levels were as follows: 12.9 (lane 1), 22.6 (lane 2), 157.7 (lane 3), 56.8 (lane 4), 74.7
(lane 5), 136.9 (lane 6). (C) No correlation between NOS3 mRNA levels and genotype at the 27 nt-ncRNA locus in intron 5 of the NOS3 gene was found.
In human alleles, two tandem-repeated homologous motifs were found in typical allele-specific order (top right). The number of patients analysed for
each group is stated (n).
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and its zygosity for all patients. No correlation between
different 27-bp VNTR genotypes and NOS3 mRNA levels
or placental perfusion was observed (Figure 1C).
High-5-hydroxymethylcytosine levels adjacent to the
NOS3 transcription start site (TSS) correlate with impaired
placental perfusion and enriched NOS3 mRNA
To understand the regulation of differential NOS3 expres-
sion in response to changes in placental perfusion, we
compared epigenetic biomarkers at the levels of DNA
CpG signalling between patients with normal and im-
paired placental flow indices. Initially, we analysed a
12-kb sequence fragment of the human NOS3 gene(−5 kb upstream of transcription start site (TSS) and +7
kb downstream of TSS) for putative target sites of differ-
ential 5meC/5hmeC signatures (Figure 2A) followed by
(h)MeDIP and qPCR analyses to discover whether these
putative target sites were pulled down by antibodies
specific for either 5meC or 5hmeC (Table 2, Figure 2A).
Importantly, both antibodies turned out to be highly
specific with a recovery rate of a total methylated control
fragment from input DNA exceeding 45% using the anti-
5meC mAb, whereas it was below 2.5% for total hydroxy-
methylated control DNA and below 1% for unmodified
control DNA. Using the anti-5hmeC mAb, recovery of
total hydroxymethylated control DNA was greater than
69%, whereas it was close to 0.01% for total methylated or
Figure 2 5-hydroxymethylcytosine (5hmeC) levels adjacent to the NOS3 TSS correlate with impaired placental perfusion and upregulation of
NOS3 mRNA. (A) 5meC (red line) within the NOS3 promoter exhibited a local depression in all patients with minimal variations. In contrast, the amounts
of precipitated 5hmeC-enriched DNA (green line) showed a local peak, particularly at the TSS (P4) with significant variations between individuals. In the
gene structure cartoon (below), the first 5 NOS3 exons are marked as red boxes and a black arrow indicates the TSS. CpG-enriched regions analysed by
qPCR are shown as green boxes (P1 to P6). The blue box marks the location of the 27 nt-ncRNA in intron 5. (B) 5hmeC levels at the TSS (P4), but not at
other CpG-rich loci, directly correlate with NOS3 mRNA levels.
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considerable inter- and intraindividual differences in
overall 5meC levels in the NOS3 promoter across the
analysed 12-kb fragment (Additional file 1: Data 1), but
no correlation between 5meC levels and NOS3 mRNA
levels. Interestingly, regardless of interindividual differ-
ences, a common pattern with local 5meC depression at
the TSS and elevated methylation at the boundaries was
recognizable (Figure 2A). Importantly, the amount of
5meC associated with the above-mentioned depression
was reminiscent of a hypomethylated locus within the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) pro-
moter. On the other hand, the increased levels of 5meC at
both boundaries were reminiscent of a hypermethylated
locus within the transcriptionally mostly silent testis-
specific histone 2B (TSH2B) gene (Additional file 1: Data
1). To further analyse whether the local 5meC depression
at the NOS3 TSS indicated a massive turnover of 5meC at
this site, we decided to probe the same loci as described
above for 5hmeC enrichment, since recent data suggested
that 5hmeC represents an intermediate state of DNAdemethylation by Tet protein family members [7]. Strik-
ingly, we observed an almost inverse pattern of 5hmeC
at the TSS when compared to 5meC. At this site, 5hmeC
enrichment differed significantly between individual pa-
tients and exhibited direct correlation with the grade of
impaired placental perfusion and elevated NOS3 mRNA
levels (Figure 2A,B).
Turnover of histone acetylation adjacent to the NOS3 TSS
correlates with impaired placental perfusion and
differential NOS3 expression
For transcriptional repression, 5meC presumably must
be read out by 5meCpG-binding proteins, which entails
assembly of repressive complexes. These complexes can
contain histone deacetylase (HDAC) activity [5,25-27].
Vice versa, local chromatin conformation could also
depend on 5hmeC signatures. To obtain comprehensive
insight into the epigenetic regulation of NOS3 expression,
we thus decided to analyse whether modifications of the
chromatin signature might also be involved in NOS3
regulation. Out of seven patients’ samples belonging either
Table 2 Oligonucleotides used in this study





































NOS3_intron5out+ caggcacctaccagcttagg Nested PCR/genotyping
NOS3_intron5out− ggaactggggtagcagtgg Nested PCR/genotyping
NOS3_intron5in+ ggatccagtgggggaagc Nested PCR/genotyping
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purify sufficient amounts of chromatin for chromatin im-
munoprecipitation (ChIP) followed by qPCR analyses. We
focused these analyses on histone modifications frequently
associated with the promoters of either transcriptionally
competent/active genes (histone 2A (H2A).Zac, H3K9ac)
or repressed genes (H3K9me3). Further, we targeted his-
tone 3 (H3) concomitantly modified at lysine-9 and
serine-10 (H3K9me3/S10ph), since it has been reported
that phosphorylation of serine-10 is sufficient to eject
heterochromatin protein 1 (HP1) bound at H3K9me3 [28]
thus counteracting heterochromatin formation. This selec-
tion enabled us to analyse three switch positions at one
discrete PTM target site, which could potentially be associ-
ated with biological consequences.
We found increased H2A.Zac and H3K9ac levels (ampli-
cons 4 and 5) framing a local depression at the NOS3 TSS
(amplicon 4a) in patients with impaired placental perfusion
(flow group 3, Figure 3A–C). Adjacent to the TSS and at
more distantly located regions up- and downstream, no sig-
nificant alterations between flow group 0 and flow group 3
could be observed. Remarkably, histone acetylation at two
sites flanking the TSS was directly correlated with NOS3
mRNA copy number (r2 = 0.622, p = 0.03; Figure 3D). In
two individuals (UC41/UC42) with high-NOS3 mRNA
levels, low-H2A.Zac levels at amplicon P4 were associated
with high H3K9ac and vice versa at the same site in patient
UC37 (Additional file 2: Data 2). Concerning the H3K9me3distribution, we found higher levels in flow group 3 patients
when compared to flow group 0 (Figure 3E). Import-
antly, the same patients also exhibited significantly higher
H3K9me3/S10ph levels, thus possibly counteracting het-
erochromatin formation, which could provide an explan-
ation for elevated NOS3 mRNA levels in the presence of
H3K9me3 in this case (Figure 3F). Remarkably, on an
individual base in flow group 3, the exceptionally high-
H3K9me3 levels correlated with similar H3K9me3/S10ph
increments (UC31, see Figure 3E and Additional file 2:
Data 2). Moreover, we made a complementary observa-
tion in one flow group 0 patient (UC13) who showed
H3K9me3 enrichment at amplicon 4 in the presence of
low-H3K9me3/S10ph levels at the same sites (UC13,
Figure 3E,F) suggesting that in this case H3K9me3 could
be involved in the establishment of a repressive chromatin
structure. Taken together, these observations strongly
suggest that chromatin plasticity is associated with dy-
namic PTM combinations at a given site, which may differ
between individuals.
Histone acetylation modifies NOS3 expression in HUAEC
in response to trichostatin A treatment entailed by
deferred self-attenuation
To test whether histone acetylation and NOS3 expression
are functionally connected, we studied the effects of the
HDAC inhibitor trichostatin A (TSA) on NOS3 mRNA
synthesis in primary HUAEC. Notably, contrary to naïve
Figure 3 Dynamic histone acetylation levels adjacent to the transcription start site of NOS3 correlate with impaired placental perfusion
and differential NOS3 expression. (A-B) Histone acetylation patterns differed significantly between patients with high- (green line) and low- (red line)
NOS3 mRNA levels. Interestingly, levels of H3K9ac (A) as well as H2A.Zac (B) were significantly higher surrounding the transcription start site (TSS).
(C-D) The combined illustration of H3K9ac and H2A.Zac patterns—calculated as mean of both fold changes—demonstrated an even more pronounced
effect of histone acetylation at the TSS on NOS3 mRNA levels (C) suggesting that both acetylation hallmarks have similar biological consequences.
Moreover, the overall level of acetylation around the TSS directly correlated with NOS3 mRNA levels (D). Features of the gene structure cartoon are
described in Figure 2. (E-F) H3K9me3 levels adjacent to the TSS were higher in patients with high-NOS3 mRNA levels when compared to patients with
low-copy number (E)—except for one patient with low-NOS3 mRNA copy number who also had a high level of H3K9me3 (UC13). At the same time,
patients with high-NOS3 mRNA copy number also showed an increase in H3K9me3/S10ph (F).
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pressive effect on NOS3 mRNA synthesis in response
to 12-h incubation with TSA [29]. Further, Yan et al.
reported that a 27 nt-ncRNA encoded in intron 5 of
NOS3 suppresses NOS3 expression via inhibition of
STAT3 signalling [23]. With respect to these studies,
we hypothesized that inhibition of HDAC activity using
TSA would lead to rapidly increased histone acetylation
at the NOS3 promoter and increased NOS3 mRNA
levels. Consequently, a yet unknown intrinsic negative
feedback loop would mediate post-transcriptional reduc-
tion of NOS3 mRNA over time. To test this hypothesis,
we performed time course experiments in HUAEC sup-
plemented with 1-μM TSA in order to monitor responsive
NOS3 and STAT3 expression profiles. As predicted,
NOS3 and STAT3 transcription responded in a time-
dependent manner with significant and rapid upregulation
15 min after TSA treatment followed by substantial long-
lasting downregulation (Figure 4A). The median increase
of NOS3 expression directly after TSA treatment was
54.8-fold (range 36.8–77.7), whereby it was 4.4-fold (1.7-
10.2) for STAT3 mRNA. To test whether the observed
self-attenuation causes resistance against repeated 1-μM
TSA pulse-treatments, we performed pulse-release experi-
ments and monitored the responsive expression profiles
of NOS3 and STAT3 at discrete time points as described
above (Figure 4B). Notably, upregulation of STAT3 in
response to the second pulse was substantially reduced
(33.51% of pulse 1 response), whereas we only observed
a marginal mRNA rise for NOS3 (1.39% of pulse 1
response). Upon a third TSA pulse, no significant fluc-
tuation of both NOS3 (0.09% of pulse 1 response) and
STAT3 mRNA levels (3.45% of pulse 1 response) was
observed (Figure 4B).Figure 4 Histone acetylation changes underlie NOS3 expression in HU
deferred self-attenuation. (A) Upon HDAC inhibition via trichostatin A (T
and long-lasting decrease of NOS3 mRNA levels (A). A similar pattern is see
TSA pulse leads to an initial boost of NOS3 expression followed by deferred
Expression of STAT3 α not STAT3β is induced by TSA treatment. (D) Transfe
to a significant reduction of NOS3 mRNA levels and vice versa. Thereby, th
on STAT3.However, evidence for a direct connection between
STAT3 signalling and NOS3 remains marginal to date.
Since non-redundant biological relevance of two isoforms,
Stat3α and Stat3β (encoded by two transcript variants),
is controversially discussed [30,31], we decided to dis-
criminate these isoforms. Interestingly, primarily the
transcript-variant-encoding Stat3α is expressed in HUAEC
cells. This variant was shown to be responsive to TSA
treatment in our experiments (Figure 4C). To gain deeper
insight into a putative interdependence of STAT3 and
NOS3, we analysed whether RNA interference targeting
either STAT3 or NOS3 in HUAEC might affect the
expression of NOS3 or STAT3α/β (Figure 4D). Quantita-
tive PCR analyses confirmed that both siRNAs led to
significant reduction of their target mRNAs. Importantly,
levels of STAT3α, but not STAT3β mRNA, were also sig-
nificantly decreased when NOS3 was targeted by siRNA
and vice versa (Figure 4C).
Site-specific STAT3 enrichment at the NOS3 promoter
correlates with increased turnover of H2A.Zac and
H3K9ac at the NOS3 TSS in response to hypoxia
To further analyse the dynamic of NOS3 and STAT3
expression, we made use of an in vitro cell culture model
simulating placental insufficiency by depriving HUAEC
of oxygen for 24 h [16]. This led to a significant increase
in mRNA levels for NOS3 and STAT3α, whereas levels
of STAT3β remained unchanged (Figure 5B). Import-
antly, a similar increase in STAT3α mRNA levels was
observed in patients with high- versus low-grade placental
insufficiency (Additional file 3: Data 3). We then aimed to
evaluate the functional relationship between Stat3 protein
activity and NOS3 gene expression. Using reported
Stat3-binding consensus motifs TT[N]4TT, TT[N]5TTAEC in response to trichostatin A treatment and is followed by
SA) in HUAEC, there is a rapid, up to 55-fold increase prior to a steep
n for STAT3 expression (A). (B) Treatment of HUAEC by a restricted
, continuously decreasing amplitudes upon further TSA pulses. (C)
ction of HUAEC with siRNA targeted to STAT3 or NOS3 mRNA leads
e effect of STAT3 inhibition on NOS3 is much stronger than of NOS3
Figure 5 Hypoxia induces STAT3 and H2A.Zac and H3K9ac turnover at the NOS3 promoter region. (A) Predicted STAT3 binding site in the NOS3
promoter region based on the STAT3 consensus motifs are shown. During normoxia in human umbilical artery endothelial cells (HUAEC), only one region
1554 bp upstream of the transcription start site (TSS) was enriched in immune precipitates using STAT3 specific antibodies. Enrichment significantly
increased during hypoxia with additional sequences being amplified 1,260 and 620 bp upstream of the TSS. (B) NOS3 and STAT3, particularly STAT3α
expression, is upregulated in HUAEC in response to hypoxia. (C) Enrichment of the promoter sequence 1554 upstream of the TSS in STAT3 immune
precipitates is upregulated during hypoxia in HUAECs. (D) Hypoxia induces a substantial increase in H2A.Zac and H3K9ac turnover at the NOS3 promoter
region in HUAECs.
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binding sites in the NOS3 promoter region (Figure 5A,
arrows). To quantify possible enrichment of this tran-
scription factor at these sites, we pulled down Stat3
bound to chromatin using specific antibodies followed
by qPCR. Under normal culture conditions, only one
amplicon containing the predicted −1.554-bp Stat3
binding site upstream of the TSS could be amplified,
which thus very likely harbours the primary Stat3 binding
site (Figure 5A). Strikingly, during simulated placental
insufficiency, Stat3 turnover at the −1.554-bp binding site
increased extensively (Figure 5C). Furthermore, two other
potential binding sequences, −620 and −1.250 bp, were
enriched within the immune complexes (Figure 5A). Last,
we used the model to examine the response of histone
PTMs associated with the NOS3 TSS to hypoxia. In agree-
ment with our data from clinical samples, the turnover
of H2A.Zac and H3K9ac increased significantly during
hypoxia (Figure 5D).
Self-attenuation of NOS3 is a mediated expression of
NOS3 intronic 27 nt-ncRNA
We next reinvestigated in more detail the influence of the
NOS3-intronic 27 nt-ncRNA on both NOS3 and STAT3
expressions. Recently, Zhang and colleagues reported that
ectopic expression of tandem decamers or tandempentamers leads to increased levels of 27 nt-ncRNA in
HUAEC, when compared to the expression of tandem
tetramers [33]. This suggests that higher tandem-repeat
copy numbers lead to increased amounts of mature 27
nt-ncRNA. The population frequency of penta- and tetra-
mers in human alleles exceeds by far hexamers. In our
patient’s pool, only one heterozygous hexamer(4c)|
tetramer(4a) sample was detected. Basically, the tandem
repeats analysed were composed out of variable copy
numbers of two homologous 27-nt sequence motifs (motif
1: 5′-GAAGUCUAGACCUGCUGCAGGGG UGAG-3′;
motif 2: 5′-GAAGUCUAGACCUGCUGCGGGGGUGA
G-3′) leading to a natural total range of 27 nt-ncRNA
copy numbers of 8 (4a|4a), 9 (4b|4a) or 10 (4b|4b or 4c/
4a) in the studied cohort. To investigate whether both
motifs possess redundant potency to suppress NOS3 and/
or STAT3 expression, we transfected these oligonucleo-
tides as siRNAs into HUAEC followed by analyses of
NOS3 and STAT3 expressions and the availability of
eNOS protein (Figure 6A,B). Our data confirm that deliv-
ery of both motif 1 and motif 2 leads to diminished avail-
ability of NOS3 and STAT3 mRNA (Figure 6A). We also
observed a trend towards decreased amounts of eNOS
and eNOS(Ser1177ph) in particular the 48-h post-siRNA
treatment which however was not statistically significant
using semi-quantitative Western blot analysis.
Figure 6 27 nt-siRNAs target STAT3-3′UTR and correlates with NOS3 mRNA levels in healthy infants. We used both homologous, slightly
different 27 nt-motifs as siRNA for the transfection of HUAEC (A-B). In both motifs, a significant reduction of NOS3 and STAT3 mRNA levels (A)
and a tendency to lower eNOS and eNOS(Ser1177ph) protein levels (B) were observed (A) 48 h post-siRNA treatment. No differences in 27 nt-RNA
concentrations were found between flow group 0 and 3 (C). Whereas, in infants with normal placental perfusion (flow group 0), 27 nt-RNA enrichment
correlated with lower NOS3 mRNA levels (D), no such correlation was found in infants with severe placental insufficiency (flow group 3, E).
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this negative feedback mechanism, we measured 27 nt-
ncRNA concentrations in biosamples from our patients.
Surprisingly, at first sight, we did not find any differences
between 27 nt-ncRNA concentrations when comparing
patients with normal (flow group 0) and severely impaired
placental perfusion (flow group 3) (Figure 6C). However,
in patients without impairment of placental perfusion,
enrichment of 27 nt-ncRNA correlated with lower NOS3
mRNA levels and vice versa (r2 = 0.69, p = 0.07;
Figure 6D). Importantly, such a correlation could not
been found for patients with severe placental insuffi-
ciency (r2 = 0.004, p = 0.91; Figure 6E).
NOS3-intronic 27 nt-ncRNA targets the STAT3-3′-UTR and
acts reminiscently of 5′-dominant microRNAs
The biogenesis of mature 27 nt-ncRNA remains enig-
matic. RNA interference experiments targeting Drosha
or Dicer lead to impaired 27 nt-ncRNA maturation, indi-
cating that it depends on the canonical microRNA
biogenesis pathway [33]. A precursor has not yet been
identified to date. Possibly, the whole intron could act as
a long non-coding RNA, from which 27 nt-ncRNAs are
further processed. Alternatively, the precursor RNA/pri-
miRNA simply consists of tandem-repeated 27 nt-RNA
motifs post-transcriptionally processed by an unknown
mechanism. We made an attempt to perform secondary
structure simulations of the different tandem repeats
(Figure 7A) using the mfold tool [34]. In summary, allmultimeric 27 nt-RNA tandems exhibited regular stem-
loop secondary structures with paired and mismatch
positions, regardless of being tetrameric, pentameric or
hexameric. Thus, it cannot be excluded that such struc-
tures could serve as substrate for Drosha and/or Dicer.
However, Drosha-independent non-canonical microRNA
biogenesis has also been reported [35]. Two earlier stud-
ies proposed that the mature 27 nt-ncRNA acts like a
microRNA (miRNA) targeting the 3′-UTR of STAT3
[23,36]. Yan and colleagues argued that a heptameric tar-
get sequence is harboured within the 3′-domain of the
27 nt-ncRNA (compare Figure 7B). They reported that
mutations within this motif led to a loss-of-function
phenotype in a reporter assay. In stark contrast to these
results, target recognition of miRNAs usually involves
the 5′-domain, which contains the miRNA seed region.
This finds convincing support in an elegant study [37]
using a Drosophila reporter system. The study showed
that two major groups exist—5′-dominant as well as
3′-compensatory miRNAs, wherein less complementary
5′-seed base pairing requires stronger 3′ compensatory
pairing. Furthermore, the model proposed by Yan and
colleagues is opposed by structural restrictions, since
Argonaute divides bound miRNAs into functional domains
[38]. Mismatches within the miRNA’s seed directly impair
binding of the catalytic miRNA-Argonaute complex to
its target sequence much more than mismatches in the
3′-supplementary region. We investigated the putative
targeting mechanism of the 27 nt-ncRNA. By homology
Figure 7 (See legend on next page.)
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Figure 7 Targeting of STAT3-3′UTR by 27 nt-siRNAs is reminiscent of miR targeting. (A) The biogenesis of 27 nt-ncRNA is still enigmatic.
This figure shows secondary structure simulations of the different tandem repeats exhibiting regular extended stem-loops. (B) The expression of
luciferase containing the STAT3 wild-type (wt) 3′-UTR target motif is significantly reduced when compared with luciferase containing a mutated
putative STAT3 3′-UTR recognition motif (mut). (C) Phylogenetic analyses show that the intronic 27 nt-ncRNA motif is conserved in numerous
primate species within the NOS3 gene. Analyses of the corresponding putative STAT3 recognition motifs in those primates suggest a putatively
conserved miR recognition mechanism in Catarrhini, whereas less support is given for Platyrrhini and Tarsidae. No evidence for the 27 nt-ncRNA
motif was found in species other than primates.
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in the 3′-UTR of STAT3 perfectly matching as GU
wobble to the anchor (1), to the 5′ seed (2–10) and less
complementary with the central or 3′-supplementary
region (13–16) of the 27 nt-ncRNA. Notably, the vari-
able position between motif 1 and motif 2 (R19) does
not interfere with the predicted base pairing (Figure 7B).
To test whether the motif found in the 3′-UTR of
STAT3 is a target for the putative 27 nt-ncRNA 5′-
seed, we performed in vitro reporter assays. Therefore,
we transfected HELA cells with the pmirGLO Dual-
Luciferase miRNA target expression vector containing
a large segment of either the wild-type STAT3 3′-UTR
or a homologous sequence with mutated putative target
site (Figure 7B). Cells were then transfected with the 27
nt-ncRNA oligonucleotides as siRNA, and luciferase
expression was analysed by qPCR. The 27 nt-ncRNA
caused significantly reduced levels of luciferase mRNAs
using the wild-type motif within the 3′-UTR, but not
with a mutated motif (Figure 7B). To test for evolutionary
conservation of this 27 nt-ncRNA motif, we searched gen-
ome databases for primate sequences homologous to
NOS3 intron 5. We subsequently performed sequence
alignments and identified the 27 nt-motifs. We identified
variably sized tandem repeats or singleton motifs within
various primate species (Figure 7C, Additional file 4: Data
4), which allows us to date back a common ancestor of
the 27 nt-motif at least 58 million years ago [39]. To esti-
mate whether these motifs could encode STAT3 targeting
miRNAs, we also extracted the proposed STAT3 target
sequence from the databases and analysed potential base
pairing mechanisms (Figure 7C). The proposed mechan-
ism with strong 5′-seed and central or 3′-supplementary
region matches could also hold for all great ape species,
whereas 5′-seed pairing seems to be slightly less com-
plementary in aboriginal primates, such as tarsiers for
example. Interestingly, tarsiers exhibit stronger 3′-sup-
plementary pairing to the STAT3 target consistent with
a 3′-compensatory miRNA rather than being 5′-domin-
ant. Since most miRNAs are evolutionary conserved, this
putative presence of an ancestral 27 nt-ncRNA targeting
the STAT3-3′-UTR further supports the relevance of the
proposed regulatory mechanism.Discussion
In this study, we showed that the foetal response upon
alterations in placental perfusion involves differential
expression of NOS3 in HUAEC. There was no influence
of known genotype variations as described for other dis-
orders in adult patients [40]. Importantly, NOS3 expres-
sion correlated with perfusion indices in both the foetal
and maternal circulation, thus for the first time linking
human clinical data on placental perfusion to molecular
changes in the foetus. These in vivo data are in line with
a recent in vitro study demonstrating increased NOS3
activity in HUAEC in response to hypoxia [16].
We also demonstrated that the changes observed in
response to placental insufficiency are associated with
changes of the epigenetic signatures at the NOS3 gene
locus. We noted that the 5meC level at the NOS3 pro-
moter was low in all patients without being correlated
with NOS3 expression. This corresponds well with the
observation of widespread CpG hypomethylation within
the NOS3 promoter in endothelial cells, and hypermethy-
lation in non-endothelial cells [41]. However, we found
significant differences in the level of 5hmeC adjacent to
the TSS correlating with placental and foetal perfusion
indices and NOS3 mRNA levels suggesting a regulatory
role for 5hmeC in NOS3 transcription. Mechanistically,
the overlap of a local 5meC depression with a 5hmeC peak
at the same site might be interpreted as rapid turnover of
DNA methylation at this site [7].
Next, we analysed selected histone modifications in
relation to NOS3 transcription. Similar to 5hmeC levels,
we found increased levels of H3K9ac and H2A.Zac adja-
cent to the TSS in patients with high-NOS3 mRNA
levels who suffered from intrauterine placental insuffi-
ciency. Interestingly, in patients with high-NOS3 mRNA
levels, H3K9ac and H2A.Zac seemed to be interchange-
able with patients having either highly increased turnover
of H3K9ac or H2A.Zac or moderately increased acetyl-
ation at both sites. This corresponds well to the concept
that histone acetylation adjacent to histone-DNA contact
sites could directly compensate the positive charge of ly-
sines leading to weaker interactions of the negatively
charged DNA phosphate backbone which thus counter-
acts repressive chromatin configurations [42]. Remarkably,
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ently found at two sites flanking the TSS, whereas the TSS
itself behaved relatively inert. This pattern could indicate
the existence of at least two well-positioned nucleosomes
adjacent to a nucleosome-depleted region in direct prox-
imity to the TSS in NOS3. This observation is also in line
with data presented by Fish et al. demonstrating reduced
levels of H3K9ac and H2A.Zac in HUVEC associated with
decreased eNOS expression in vitro [21].
For H3K9me3, which binds snuggly to heterochromatin
protein 1 (HP1) and hence promotes heterochromatin
formation and gene repression, we found generally low
levels in most patients independent of NOS3 mRNA
levels. This is in line with the status of a transcriptionally
competent gene which is also reflected by the low-5meC
levels at the NOS3 promoter observed in all patients.
Occasionally and somewhat unexpectedly, we also observed
H3K9me3 enrichment in association with high-NOS3
mRNA levels. However, further investigation revealed that
concomitantly serine-10 phosphorylation occurred at the
same site (H3K9me3/S10ph) in the affected individuals
most likely representing a binary methylation/phosphoryl-
ation switch, which was reported to counteract HP1 bind-
ing and heterochromatin formation, thus disabling the
repressive competence of H3K9me3 [28,43]. This status is
also somewhat reminiscent of a poised gene associated
with bivalent PTM, i.e. the existence of opposing histone
modifications at the same nucleosome. Notably, in one
patient’s sample exhibiting low-NOS3 mRNA amounts in
combination with enriched H3K9me3, H3K9me3/S10ph
was absent. Here, H3K9me3 is likely to be involved in the
establishment of a repressive chromatin structure at the
NOS3 promoter. Overall, the variances in histone acetyl-
ation and methylation patterns observed in this study
clearly confirm that chromatin signatures involved in the
regulation of a specific gene (such as NOS3) act in com-
bination and are interdependent. In clinical specimens
from individual patients, they thus need to be interpreted
with caution always considering the greater context [44].
In the second part of this study, we aimed to provide
deeper mechanistic insights into NOS3 gene regulation
using an in vitro cell culture model. This was important,
because a previous study by Rossig and co-workers
reported a marked reduction in NOS3 expression upon
treatment of endothelial cells with the HDAC inhibitor
TSA for at least 12 h suggesting—in contrast to our
in vivo findings—a repressive effect of histone acetylation
on NOS3 expression [29]. One possible explanation for
this contradictory observation could be a negative feed-
back mechanism counteracting the increased NOS3
transcription enforced by histone acetylation possibly
involving a 27 nt-ncRNA encoded in NOS3 intron 5 as
proposed earlier [36]. To evaluate this hypothesis, we
performed TSA time course experiments in HUAECalso including STAT3 in these analyses, which has been
previously linked to NOS3 regulation [23,45]. We could
confirm that prolonged TSA treatment indeed resulted
in a marked reduction in NOS3 mRNA copy number.
However, short-termed treatment significantly increased
the NOS3 mRNA copy number. Importantly, a parallel
pattern was observed for STAT3 mRNA. Pulse-release
experiments with TSA moreover showed that the deferred
self-attenuation effect was sustainable. This observation is
in agreement with a negative feedback loop entangled with
NOS3 expression, which is possibly driven by a putatively
co-processed 27 nt-ncRNA encoded in NOS3 intron 5
[36] and involves targeting and cleavage of STAT3 mRNA
[23]. To explore this possible connection, we aimed to
characterize the functional relationship between NOS3
and STAT3 expressions as well as Stat3 protein function.
With respect to known Stat3-binding motifs [32], we
identified several potential binding sites within the NOS3
promoter. Using the HUAEC hypoxia model for placental
insufficiency [16], we showed that Stat3 selectively bound
to one of the predicted sites (namely −1.554 bp up-
stream of the TSS). Also Stat3 turnover was significantly
increased in the course of hypoxia, strongly suggesting
a functional connection between Stat3 and NOS3 regu-
lation. In addition, dynamics of NOS3 expression and
histone acetylation patterns at the NOS3 TSS in response
to hypoxia perfectly corresponded to data obtained from
clinical samples.
Next, we explored the mechanism of self-attenuation by
intronic 27 nt-ncRNA using its corresponding sequence
for RNA interference in HUAEC cultures. As hypothe-
sized, STAT3 and NOS3 mRNA levels decreased signifi-
cantly in response to treatment with both 27 nt-ncRNA
motifs found in the human genome, thus giving further
support to the proposed concept of a negative feedback
mechanism. Importantly, we were also able to demonstrate
that 27 nt-ncRNA levels correlated with NOS3 mRNA
levels in patients with normal placental flow whereas this
relationship seemed to be dissolved in patients with severe
placental insufficiency. This might be an indicator for a
more permanent disruption of epigenetic regulatory mech-
anisms in these infants. If so, this possibly predisposes these
patients for vascular disorders later in life.
Since previous hypotheses on the 27 nt-ncRNA target-
ing mechanism did not seem to hold with regard to
current models of miRNA targeting principles, we decided
to reinvestigate the underlying mechanisms using an
in vitro reporter assay as well as phylogenetic analyses.
These experiments enabled us to propose a novel hypoth-
esis of STAT3-3′-UTR targeting by the 27 nt-ncRNA,
which is reminiscent of 5′-dominant miRNA targeting,
including perfect anchor and seed matching, and therefore
most probably fulfilling the requirements of target match-
ing and for the assembly of a functional Argonaute-miRNA
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be conserved in a large number of primate species.
Conclusions
Overall, our study provides comprehensive evidence
how an adverse intrauterine milieu directly influences
human foetal gene expression by means of various levels
of gene regulation in vascular endothelial cells, including
CpG signalling, chromatin plasticity and non-coding
regulatory RNA. Whether the observed changes are revers-
ible or sustained remains an open problem to address. Due
to ethical concerns, this question is currently impossible to
answer in human individuals given the methodology avail-
able. However, epidemiological studies reporting correlation
between epigenetic signatures at the NOS3 gene locus in
HUAEC and obesity as well as bone mineral content sug-
gest that a hypoxia-induced epigenetic memory state might
persist [46]. Such persistence would provide a pathophysio-
logical explanation for the linkage between impaired foetal
growth and later vascular abnormalities observed in numer-
ous epidemiological studies [47]. In theory, the epigenetic
signature at the NOS3 locus at birth might define an indi-
vidual baseline level of NOS3 transcription for further life.
Alterations of this baseline might subsequently modify the
bandwidth of variation in which an individual can respond
to adverse events later in life. This in turn could explain the
impaired endothelial vascular response observed in patients
who were exposed to an adverse intrauterine milieu.
Methods
Written informed consent for human specimen was
obtained from all legal guardians. Ethical approval for
this study was obtained from the Witten/Herdecke Uni-
versity ethics committee. All work has been conducted
according to the principles expressed in the Declaration
of Helsinki.
Nomenclature
The authors of foregoing studies use deviating annota-
tion of the tandemly repeated 27 nt-ncRNA VNTR;
namely, it is annotated being encoded within NOS3 in-
tron 4. We refer to human NOS3 mRNA [RefSeq Gene
NM_000603] encoded on chromosome 7q36, GenBank
ID 4846, which spans a 23.54-kb region from base
150688144 to 150711687 [NC_000007.13]. Thereafter,
NOS3 mRNA encoding the canonical transcript variant
1 derives from 27 introns, and the 27-bp tandem repeat
is located within intron 5 between exons 5 and 6.
Patients
Patients were recruited over a 6-month period. Eligible
infants obtained Doppler examination of placental and
foetal circulation 12–24-h predelivery. GA estimation relied
on ultrasound classification before week 14 of gestation.We aimed to depict the whole gestational age range and to
include ten patients per flow group (see below). Epidemio-
logical parameters, hospital course data and the outcome
were collected. Foetuses with gestational diabetes were
excluded since resistance and pulsatility indices differ
from normal patients without correlation to foetal growth
parameters in these patients [48,49].
Placental and foetal perfusion assessment
Patients were grouped with respect to blood flow character-
istics in the uterine artery (UA), the mediocerebral artery
(MCA), and the ductus venosus (DV) as follows [50]:
 group 1: abnormal UA pulsatility index (PI) >2
standard deviations (SD) above mean, or absent
UA end-diastolic flow, and normal MCA PI
(mean ± 2 SD);
 group 2: abnormal UA PI >2 SD above mean,
or absent or reverse UA end-diastolic flow, and
abnormal MCA PI (mean < 2 SD) and normal DV
PI (mean ± 2 SD);
 group 3: absent or reverse UA end-diastolic flow,
and abnormal MCA PI (mean < 2 SD), and abnormal
DV PI (mean > 2 SD, a-wave present or absent or
reverse end-diastolic flow).
HUAEC isolation and cell culture
Immediately after delivery, umbilical cords were trans-
ported on ice from the maternity ward to the laboratory.
HUAEC were separated as described previously [51].
RNA was extracted using TRIzol (Life Technologies) and
quantified at 260 nm. RNA integrity was assessed by agar-
ose gel electrophoresis. For cDNA synthesis, we used 500
ng RNA per sample using the QuantiTect Reverse Tran-
scription kit (Qiagen). DNA was isolated by phenol:chloro-
form:isoamylic alcohol extraction. For in vitro experiments,
HUAEC (Promocell) were cultivated upon manufacturer’s
recommendations. For HDAC inhibition, HUAEC were
treated with 1-μM TSA. Hypoxia experiments were per-
formed using a hypoxia incubator chamber (STEMCELL
Technologies, Grenoble, France) exposing cells to a ppO2
of 0.1 bar corresponding to an oxygen fraction of 10% for
24 h. Control experiments were performed under normoxic
conditions (ppO2 = 0.21 bar).
Gene expression analyses
Gene expression analyses were performed using qPCRana-
lyses on a Rotor-Gene 6000 (Qiagen). For PCR reactions,
QuantiTect SYBR Green qPCR Master Mix (Qiagen) con-
taining Hot Start Taq DNA polymerase and SYBR Green
was used. Primers were used as listed in Table 2. The
expression of genes of interest was normalized to at least
three out of five housekeeping genes (BACT, GAPDH,
PECAM1, RPL19, VIL1). Following TSA experiments, the
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interference of this drug with the chromatin state of nuclear
housekeeping genes was expected. PCR conditions were as
follows: 95°C for 15 min, 40× [95°C for 15 s, 60°C for 30 s].
Melting of PCR product was done using a gradient from
55°C to 95°C rising in 0.5°C increments. For relative com-
parative quantification of gene expression fold changes,
we utilized the ΔΔCt method [52] using at least three
housekeeping genes for normalization.
Genotyping
Polymorphism and zygosity of the NOS3 intron 5 27 nt-
ncRNA VNTR was determined by PCR or, in some
cases, nested PCR (Table 2). PCR fragments were cloned
into the pGEM-T easy vector (Promega) prior to Sanger
sequencing (GATC Biotech). Homozygosity was evalu-
ated by at least five replicates.
Antibodies
Primary antibodies used in this study were as follows:
1. Mouse anti-5meC (Diagenode mAb33D3C15200081),
2. Rat anti-5hmeC (Diagenode mAb633HMC-020),
3. Rabbit anti-H2A.Zac (Diagenode pAb-173-050),
4. Rabbit anti-H3K9ac (Active Motif pAb#39137),
5. Rabbit anti-H3K9me3 (Active Motif pAb#39161),
Rabbit anti-H3K9me3S10ph (Diagenode pAbCS-128-
100), 5. Rabbit anti-eNOS (Cell Signalling Technologies
pAb#9572), 6. Rabbit anti-eNOS Ser1177ph (Cell Signal-
ling Technologies mAbC9C3 #9570), 7. Rabbit anti-
H3K4me3 (Diagenode pAbCSP-030-050), 8. Rabbit
anti-α-Tubulin (Sigma Aldrich mAbDM1A T9026) and
9. Rabbit anti-Stat3 (D3Z2G, Cell Signalling Technolo-
gies mAb#12640).
(Hydroxy-)methylated DNA immunoprecipitation and
qPCR analyses
Analyses of selected CpG-rich sites were performed by
(h)MeDIP. Fractions (300 μl) of genomic DNA (100 ng/μl)
were sheared on ice by ultrasonic treatment using the
Diagenode Bioruptor UCD-200 (12 cycles, 30 s ‘ON’, 30 s
‘OFF’). Most resulting fragments had sizes between ~200–
400 bp. These fractions were denatured for 10 min at
95°C and then immunoprecipitated overnight at 4°C in
a rotating wheel using 1 μg of mouse monoclonal anti-
5meC antibody 33D3 or rat anti-5hmeC antibody. For
later comparison, ‘input’ samples were collected. Subse-
quently, immunocomplexes where separated from suspen-
sion using DiaMag protein A-coated magnetic beads
(Diagenode), leading to enrichment of methylated DNA
fragments. Following several washes, DNA was purified
from either ‘input’ or immunoprecipitated samples prior
to qPCR analyses. Primer pairs for amplicons correspond-
ing to putative sites with dynamic 5meC or 5hmeC signa-
tures were designed after screening RefSeq sequences forthe presence of CpG-rich regions 5,000 bp up- and down-
stream of the transcription start site using EMBOSS
CpGplot (Table 2). Control primers representing an
amplicon with low- (GAPDH) or high-5meCpG content
(TSH2B) were purchased from Diagenode (pp-1044/pp-
1041). PCR conditions were as follows: 95°C for 15 min,
40× [95°C for 15 s, 60°C for 30 s]. Melting of PCR product
was done as described above. The recovery of 5meCpG or
5hmeC DNA from total ‘input’ DNA following (h)MeDIP
experiments was calculated as follows:
% IP=total inputð Þ ¼ AE Ct 10%inputð Þ‐log2DFð Þ‐Ct IPð Þ½ 
 100%
Abbreviations: AE (amplification efficiency); Ct (cycle
threshold values obtained from exponential phase of the
PCR reaction); the dilution factor (DF) 10 corresponds
to 10% ‘input’ sample—thus, the resulting compensatory
factor in our experiments was 3.32.
Chromatin purification and ChIP assays
Chromatin was purified from HUAEC isolated from
seven individuals belonging to the low- or high-level
NOS3 expression groups. Cells were fixed in PBS/1%
formaldehyde for 10 min at room temperature, washed
with PBS and incubated with glycine stop solution, prior
to additional washing with PBS. Cells and nuclei were
then homogenized in ice-cold ChIP buffer (50 mM
NaCl; 50 mM Tris–HCl, pH 7.5; 0.1 mM PMSF; 5 mM
EDTA; 0.1% SDS) using a Qiagen TissueRuptor device.
Following centrifugation for 10 min at 13.000 rpm in a
microcentrifuge at 4°C, the supernatant containing the
soluble chromatin fraction was collected, and the chro-
matin concentration was measured at 260 nm using a
NanoPhotometer (Implen). Portions of 25-μg (0.1 ng/μl)
chromatin were sheared by ultrasonic treatment using a
Bioruptor UCD-200 (Diagenode) and 25× [30 s ON/30 s
OFF] at position ‘high’. Chromatin fragment size was
controlled on agarose gels, and one of the chromatin
aliquots was saved as input. For ChIP 25 μg sheared
chromatin was incubated with the respective antibody in
a rotator for 16 h at 4°C in a total volume of 250 μl ChIP
incubation buffer. Subsequently 25 μl protein G mag-
netic beads (Active Motif ) were added and incubated for
4 h at 4°C rotating. Protein G magnetic beads were sepa-
rated using a magnetic rack and washed repeatedly. To
elute DNA fragments enriched by immunoprecipitation,
immunocomplexes were incubated with elution buffer
(1% SDS, 10 mM EDTA, 50 mM Tris–HCl, (pH 8.1)) for
30 min at 65°C on a shaker. Eluted immunocomplexes
were treated with proteinase K. Quantitative PCR ana-
lyses were performed using a Rotorgene 6000 (Qiagen).
The relative amounts of specifically immunoprecipitated
DNA were estimated as ‘percent of input’ and quantified
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Primer pairs were used as described in Table 2.
RNA interference and reporter assay
For HUAEC transfection, oligonucleotides corresponding
to two different 27 nt-ncRNA motifs were used. For trans-
fection into HeLa cells, siRNAs targeted to STAT3 or
NOS3 were used. HiPerFect transfection reagent (Qiagen)
was used. Effects of 27 nt-ncRNA or siRNAs targeting
STAT3 or NOS3 on the expression of NOS3 or STAT3
were assessed in HUAEC 72 h post-transfection by qPCR
as described above. For other experiments, we cloned a
1.160-bp DraI/NheI-fragment from the STAT3-3′-UTR
containing either the wild-type or a mutated miRNA
targeting site into the pmirGLO Dual-Luciferase miRNA
target expression vector (Promega). These constructs
were transfected into HeLa using Lipofectamine 2000
(Life Technologies) 48 h prior to transfection of siRNAs
targeting the [luciferase]-STAT3-3′-UTR. Here, the levels
of luciferase mRNAs were measured by qPCR 24 h post-
transfection.
MiR library generation and qPCR.
From selected specimens, we prepared microRNA librar-
ies. Therefore, each sample was tagged with multiplex
sequencing barcodes. Total RNA was separated by poly-
acrylamide gel electrophoresis. Gel fragments corre-
sponding to 15 to 35 nt RNA molecules were cut and
RNA was eluted. The obtained small RNA fraction was
directly used for the construction of libraries in four
steps. Step 1: Ligation of DNA oligonucleotides to the
3′-end of the RNA; Step 2: Ligation of RNA or, res-
pectively, chimeric RNA/DNA oligonucleotides to the
5′-end of RNAs; Step 3: cDNA library synthesis by re-
verse transcriptase; Step 4: qPCR analyses of the cDNA
libraries using pairs of Illumina (San Diego, California,
US) index primers, which corresponded to the adapter
oligonucleotides used, and a 27 nt-ncRNA-specific pri-
mer (5′-tagacctgctgcrggggtgag-3′) were performed as
described above.
Statistical analysis
Mean expression levels were calculated at least from
triplicate real-time PCR measurements. In all figures,
data are presented as median ± interquartile range
(IQR), minimum and maximum, and values for p < 0.05
were considered statistically significant unless depicted
otherwise. Significance testing was performed using a
one-way ANOVA test for values with Gaussian distribu-
tion and Mann–Whitney U test for values without
Gaussian distribution. The Kolmogorov-Smirnov test
was utilized to rule out non-Gaussian distribution. All
analyses were performed using GraphPad version 5.01
(La Jolla, CA USA).Additional files
Additional file 1: Data 1. Interindividual 5meC and 5hmeC signatures at
the NOS3 gene locus. Each column colour represents one individual patient
analysed.
Additional file 2: Data 2. Interindividual histone modification
signatures at the NOS3 gene locus. Results of ChIP-qPCR using the same
sites as in Figure 3. Each line represents an individual patient. Green lines
belong to flow group 3 and red to flow group 0.
Additional file 3: Data 3. Relative STAT3α mRNA levels in patients with
high- and low-grade placental insufficiency. Results of qPCR. Ten patients
were included in flow group 0 and seven in flow group 3. Fold changes
were calculated using the Delta Delta CT method.
Additional file 4: Data 4. Alignment of primate genomic sequences
homologous to human NOS3 intron 5. The 27 nt-motif containing loci
are marked by */+ above the aligned sequences.Abbreviations
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